An experimental drug Xyotax was successful in shrinking stomach and esophagus tumors in four out of 12 cancer patients, according to its maker Cell Therapeutics. The other patients had at least 50 percent reduction in their tumor size, the company said.
The medicine is to be given along with radiation, it added. The company said a follow-up trial is in progress to ascertain exactly how the medicine is useful. A study on the effects is published in this month's issue of the American Journal of Clinical Oncology.
Xyotax is used in combination with radiation and cisplatin, a chemotherapy drug. The main aim of the study was to check what dose would be tolerated by the patients. However it must be noted that not all patients were evaluated.